INTRODUCTION {#s1}
============

The term congenital myopathy (CM) encompasses a spectrum of clinically, histologically, and genetically variable neuromuscular disorders, many of which are caused by mutations in genes for sarcomeric proteins. Classified mainly on the basis of their histopathology, they share many clinical features, including hypotonia and proximal or generalized, and often nonprogressive, muscle weakness typically present from birth. The severity of weakness and disability varies widely from neonates with profound hypotonia and generalized weakness to patients with weakness that first manifests during childhood through delayed motor milestones or later in life with proximal weakness ([@MCS004184MARC23]; [@MCS004184MARC12]). Serum creatine kinase levels are usually within normal limits but may be mildly to moderately elevated. The clinical manifestations of most CMs are limited largely to skeletal muscle, consistent with the restricted expression patterns of many CM genes; however, mutations of more broadly expressed genes, such as that for myotubularin, may lead to subtle findings in other organ systems ([@MCS004184MARC14]; [@MCS004184MARC2]), and defects in genes with both skeletal and cardiac muscle expression, such as titin, may lead to either a predominantly skeletal or cardiac myopathy or both ([@MCS004184MARC15]; [@MCS004184MARC4]).

Traditionally histology has been used as the basis to subcategorize the CMs, and diagnoses are based on the presence of diagnostic pathological findings in the context of primary hypotonia or weakness. Reflecting their relatively nonprogressive course, muscle biopsies typically lack evidence for a dystrophic process of myofiber death and regeneration but instead are characterized by relatively stable and unique ultrastructural defects. Some of the most commonly recognized conditions include the nemaline (rod body) myopathies (NMs), core myopathies (such as central core and multiminicore diseases), the centronuclear/myotubular myopathies, and isolated fiber-type disproportions. Each clinicopathological diagnosis is genetically heterogeneous. For example, although recessive nebulin gene (*NEB*) mutations are responsible for about half of NM cases ([@MCS004184MARC20]), there are upward of a dozen different genes associated with NM ([@MCS004184MARC23]; [@MCS004184MARC12]). Furthermore, mutations of many CM genes can cause a variety of distinct histopathological and clinical presentations---for example, mutations of the *TPM2* gene encoding skeletal muscle tropomyosin, which can present as cap myopathy, NM, congenital fiber-type disproportion (CFTD), Escobar syndrome, or distal arthrogryposis ([@MCS004184MARC21]). Further complicating diagnosis is the fact that many of these features can be found together---for example, families in whom some affected members may have either nemaline rods or CFTD or both ([@MCS004184MARC21]) or co-occurrence of rods and cores ([@MCS004184MARC1]).

Fiber-type disproportions, particularly with abnormally small type 1 fibers, are fairly common in muscle biopsies from patients with a variety of CMs, and when paired with prominent nemaline bodies or cores are typically considered secondary nondiagnostic findings. However, patients with primary skeletal muscle weakness whose muscle exhibits only small type 1 fibers have been classified as having CFTD ([@MCS004184MARC10]; [@MCS004184MARC5]). Most cases of CFTD are associated with mutations in *TPM3*, encoding the type 1 fiber-specific slow α-tropomyosin ([@MCS004184MARC7]; [@MCS004184MARC18]), but there is a plethora of other muscle genes whose mutations have been found in patients meeting criteria for CFTD, including *ACTA1* ([@MCS004184MARC17]), *MYH7* ([@MCS004184MARC32]), *RYR1* ([@MCS004184MARC8]), *SELENON/SEPN1* ([@MCS004184MARC6]), and *TPM2* ([@MCS004184MARC9]). Mutations of the *LMNA* gene, coding for lamin A/C, have also been identified in several Japanese patients with fiber-type disproportion, although these cases were characterized by type 2 fiber hypertrophy rather than type 1 hypotrophy, raising the question of whether they qualify as classical CFTD ([@MCS004184MARC16]). Finally, although these conditions are exclusively skeletal myopathies, type 1 fiber disproportion and weakness have also been found in association with cardiomyopathy in infants with ventricular/slow-twitch skeletal regulatory myosin light chain (*MYL2*) mutations ([@MCS004184MARC34]).

We subjected a cohort of patients with a variety of CM diagnoses to diagnostic gene panel sequencing of 43 genes associated with primary skeletal or cardiac myopathies. Here we describe one unusual case in whom we identified a predicted pathogenic homozygous frameshift variant in *MYL2* as well as a heterozygous truncating nebulin (*NEB*) mutation. Because truncating null mutations of *NEB* are a known cause of NM, this case forced a reappraisal of the diagnosis and consideration of potential digenic inheritance. Although ultimately the infant\'s phenotype was considered to be fully explained by the homozygous *MYL2* variant, the secondary finding of a pathogenic *NEB* mutation illustrates an increasingly common dilemma in cases subjected to targeted gene panel testing.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The proband was a boy who presented with generalized hypotonia and head lag at birth. He was delivered at full term by cesarean section because of decreased fetal movement and bradycardia during induction. He had normal birth weight, length, and head circumference. Newborn exam revealed normal first and second heart sound with gallop rhythm and palpable liver at the right costal margin, as well as generalized hypotonia and diminished reflexes. Echocardiogram was performed at 11 d of age and revealed patent foramen ovale with left to right shunt and right atrial enlargement. He was discharged home with no respiratory or feeding support. His mother was a primigravida 20-yr old with learning disability and hearing loss; she denied smoking, drinking, or using illicit drugs before or during pregnancy. She had multiple ultrasound studies that were remarkable only for polyhydramnios. The father was a healthy 20-yr old with no particular medical concerns, and there was no family history of neuromuscular or genetic disorders on either side. The proband continued to show poor head control and generalized hypotonia and weakness throughout the neonatal period and beyond. A vastus lateralis biopsy performed at 5 mo of age because of persistent muscle weakness and hypotonia revealed variability in fiber size with checkerboard pattern of 1:1 ratio of type 1 and type 2 fibers exhibiting hypotrophy of type 1 fiber size in comparison to the type 2 fibers ([Fig. 1](#MCS004184MARF1){ref-type="fig"}). Gomori trichrome--stained light micrographs and electron microscopy (EM) showed no evidence of ragged red fibers or nemaline rods, and oxidative stains revealed no evidence of cores, targetoid, or target fibers. Genetic testing was performed for DNA polymerase γ, catalytic subunit (*POLG*) and Noonan syndrome genes (*PTPN11*, *SOS1*, *KRAS*, *RAF1*, *BRAF*, *MAP2K1*, *MAP2K2*, and *HRAS*), all of which were normal. There was no histopathologic evidence of Pompe disease and GAA enzyme-level testing was normal. Muscular dystrophy was considered unlikely given the histopathologic findings and normal serum creatine kinase level.

![Microscopic examination substantiates the diagnosis of congenital fiber-type disproportion (CFTD). (*A*) Gomori trichrome staining does not reveal ragged red fibers or rimmed vacuoles. No definite nemaline rods are seen. Intramuscular nerve twigs are myelinated. (*B*) NAHD-TR-reacted sections reveal no cores, targetoid, or target fibers. Slight predominance of type 1 fibers is seen. Type 1 fibers are significantly smaller than type 2 fibers (mean type 2 fiber diameter-mean type 1 fiber diameter/mean type 2 fiber diameter = 40%). (*C*) ATPase (pH 9.4) staining reveals the slight predominance of type 1 fibers and type 1 fiber hypotrophy. (*D*) Electron microscopy (EM) does not show any evidence of nemaline bodies.](MCS004184Mar_F1){#MCS004184MARF1}

At age 5 mo, the proband was admitted to hospital in decompensated heart failure and intubated on inotropic support. He was stabilized and successfully extubated and sent home on captopril, digoxin, Lasix, aspirin, and ubiquinone while being evaluated for heart transplant. One month later, he presented to the emergency department in what appeared to be decompensated cardiogenic shock, with severe respiratory distress, poor peripheral perfusion, and high lactate level (7.8 mmol/L). Again, he was admitted and intubated on inotropic support in the cardiac intensive care unit. Echocardiography revealed left ventricular dilatation, mild to moderate mitral valve regurgitation, and left atrial enlargement, with left ventricular function moderately to severely decreased with shortening fraction of 12% and ejection fraction of 23%. Following an unsuccessful attempt to extubate, respiratory support was withdrawn 1 wk later and the patient passed away.

Genomic Analyses {#s2b}
----------------

Written informed consent for research-based genetic testing was obtained from both parents under the supervision of the Boston Children\'s Hospital Institutional Review Board. Panel testing of 43 neuromuscular disease-related genes ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004184/-/DC1)) led to the identification of four variants of particular concern for potential causal relationships to the proband\'s condition ([Table 1](#MCS004184MARTB1){ref-type="table"}; [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004184/-/DC1)). The proband was homozygous for variant NM_000432.3:c.188del, p.(Asn63Metfs\*7) in *MYL2*, predicted to be pathogenic according to ACMG criteria ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004184/-/DC1); [@MCS004184MARC28]). In addition, he had a paternally inherited heterozygous truncating *NEB* variant NM_001271208.2:c.25435C\>T, p.(Gln8479\*) predicted to be pathogenic. Both of these were Sanger confirmed in the proband and his parents ([Fig. 2](#MCS004184MARF2){ref-type="fig"}). The patient was also heterozygous for a titin (*TTN*) variant NM_001267550.2:c.33513_33515dup, p.(Glu11172dup) and hemizygous for NM_004021.2:c.3669_3681del, p.(Asp1223Glufs\*6) in the *DMD* gene, both of which were later determined to be benign or likely benign ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004184/-/DC1)).

![(*A*) DNA Sanger sequencing results of the proband ("P," 1053-1, *top* tracing), mother ("M," 1053-2), and father ("F," 1053-3), illustrating the myosin light chain-2 (MYL2) c.188del p.(Asn63Metfs\* 7) variant (arrowhead). Sequencing reads for parents are shown in both directions, demonstrating that they are heterozygous and proband homozygous for the mutation. (*B*) The proband ("P," *top*) also has heterozygote truncating nebulin (NEB) mutation c.25435C\>T p.(Gln8479\*) (arrowhead). The father ("F," *bottom*), but not the mother ("M," *middle*) also carries this heterozygous variant.](MCS004184Mar_F2){#MCS004184MARF2}

###### 

Variant table

  Gene     Chr   HGVS DNA reference                 HGVS protein reference             Variant type   Predicted effect   dbSNP ID       Genotype       ClinVar ID
  -------- ----- ---------------------------------- ---------------------------------- -------------- ------------------ -------------- -------------- ------------
  *MYL2*   12    NM_000432.3: c.188del              NP_000423.2: p.(Asn63Metfs\*7)     Deletion       Frameshift         rs1177936172   Homozygous     NA
  *NEB*    2     NM_001271208.2: c.25435C\>T        NP_001258137.2: p.(Gln8479\*)      Substitution   Stop-gained        rs778104284    Heterozygous   NA
  *TTN*    2     NM_001267550.2: c.33513_33515dup   NP_001254479.2: p.(Glu11172dup)    Duplication    Insertion          rs368327166    Heterozygous   46889
  *DMD*    X     NM_004021.2: c.3669_3681del        NP_004012.1: p.(Asp1223Glufs\*6)   Deletion       Frameshift         rs752332058    Hemizygous     201754

(Chr) Chromosome, (HGVS) Human Genome Variation Society, (NA) not available.

DISCUSSION {#s3}
==========

We report a novel case of CFTD and infantile onset cardiomyopathy associated with pathogenic variants in the *MYL2* and *NEB* genes. Myosin light chain-2 (*MYL2/MLC-2*) is a major sarcomeric protein of the thin filament in mammalian striated muscle of ∼19 kDa and 166 amino acids in length ([@MCS004184MARC31]). This myosin regulatory light chain is expressed in slow skeletal, type 1 fibers, as well as in ventricular cardiac myocytes, where it plays a role in cross-bridge cycling kinetics and calcium-dependent cardiac muscle contraction. Dominant missense mutations were first shown to be associated with hypertrophic cardiomyopathy ([@MCS004184MARC25]), but recently recessive frameshift mutations, affecting the last exon and associated with severe reduction or loss of detectable protein, were reported to cause a fatal infantile cardiomyopathy, with skeletal muscle involvement similar to that of our proband ([@MCS004184MARC34]).

Nebulin is a fundamental structural component of the skeletal muscle sarcomeric thin filament and is not expressed in the heart. It has 183 exons spanning 249 kb of genomic sequence, and recessive loss of function, and some missense variants, are the most common cause of NM ([@MCS004184MARC11]). Our analysis concluded that the proband\'s severe infantile cardiomyopathy and lack of evidence for nemaline rods were most consistent with the effects of the homozygous frameshift variant in *MYL2*, c.188del, p.Asn63Metfs\*7. A single heterozygous allele of this variant has been reported in a healthy female from the Finnish cohort in gnomAD, for an overall population allele frequency of 3.976 × 10^−6^ and has not been seen in any other population or disease-specific databases including 1000 Genomes, the Human Gene Mutation Database, or The Leiden Open Variation Database. Indeed, there are no instances of individuals homozygous for truncating *MYL2* variants in the entire gnomAD data set. *MYL2* c.188del p.(Asn63Metfs\*7) has a scaled CADD score of 35 ([@MCS004184MARC27]) and, according to ACMG criteria, can be classified as "pathogenic" ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004184/-/DC1)).

Recessive stop-gain and frameshift variants such as the *NEB* p.(Gln8479\*) found in our proband occur throughout the gene and are invariably disease-causing when present in a biallelic relationship with another predicted truncating variant ([@MCS004184MARC20]). Residue Gln8479 is in the last exon of the major muscle transcript, so truncation at this point may or may not destabilize the transcript; however, there are least two additional pathogenic truncating variants distal to p.Gln8479 in the nebulin Leiden Open Variation Database ([@MCS004184MARC13]), supporting a pathogenic interpretation for this variant, which also has a high scaled CADD score of 60. Nevertheless, all *NEB* mutations reported to date have invariably been recessive, and careful inspection of the panel data, including VisCap analysis for copy-number variation indicative of a gross deletion or duplication ([@MCS004184MARC26]), failed to identify a second potentially pathogenic *NEB* allele (data not shown), making this paternally inherited heterozygous variant less likely to be a significant contributor to disease in our proband. Furthermore, although mutations of nebulin have previously been associated with a variety of clinical presentations, including NM ([@MCS004184MARC24]), early-onset distal myopathy without nemaline bodies ([@MCS004184MARC33]), a distal form of NM ([@MCS004184MARC19]), core-rod myopathy with generalized muscle weakness ([@MCS004184MARC29]), and a childhood-onset distal myopathy with rods and cores ([@MCS004184MARC30]), none of these conditions feature significant cardiac pathology, consistent with the lack of *NEB* expression in the heart.

Although nebulin and myosin light chain-2 are not known to directly bind or interact, they have close functional associations because of their respective roles in sarcomeric thick and thin filaments, respectively. Therefore, it is worthwhile to consider whether heterozygosity for the truncating *NEB* variant might function as a modifier for the effects of the homozygous *MYL2* variant in skeletal muscle. However, the absence of nemaline rods on Gomori trichrome--stained light micrographs and on electron micrographs failed to provide evidence in support of this hypothesis, and the clinical presentation was entirely consistent with previous reports of patients with *MYL2* skeletal and cardiomyopathy.

Variants in the titin gene, *TTN*, and in that for dystrophin, *DMD*, were also flagged in the initial analysis but were more easily excluded from further consideration. The NM_001267550.2:c.33513_33515dup, p.(Glu11172dup) variant in *TTN* is predicted to be likely benign or benign in ClinVar largely based on its allele frequency of up to 0.0179 in Europeans and presence of 24 homozygotes across all populations in gnomAD. Given that we have also seen this allele in individuals with no evidence for a titin-related myopathy, we considered this unlikely to be a contributing factor to our proband\'s condition.

The *DMD* variant NM_004021.2:c.3669_3681del, p.(Asp1223Glufs\*6) was also considered unlikely to be relevant. Not only did the proband have normal CK levels and absence of dystrophic findings on muscle biopsy, but this 13-base indel is in the 3′ untranslated region of the large primary skeletal muscle dystrophin transcript and affects only the very carboxyl terminus of the minor Dp71 and Dp141 transcripts. Given that this variant is present at an allele frequency of 0.00025 in gnomAD, including 13 hemizygous males ranging in age from 30 to 75, we consider it likely benign, which is consistent with an entry in ClinVar.

Clinical heterogeneity resulting from variable expressivity associated with some genes and variants is common among neuromuscular disorders: The same genetic mutation may lead to different pathological features in members of the same family or in the same individual over time ([@MCS004184MARC3]). For example, mutations in *TPM3* have been reported in both CFTD and nemaline myopathy (NM) in members of the same family ([@MCS004184MARC18]). Age, genetic modifiers, environmental factors, or the site of the muscle biopsy may influence the pathological appearance of skeletal muscle ([@MCS004184MARC22]). Another example is mutations of *SELENON* (formerly *SEPN1*), which can result in rigid spine muscular dystrophy, desmin-related myopathy with Mallory body-like inclusions, or CFTD ([@MCS004184MARC12]). These examples suggest that different mutations in the same gene can affect different pathogenetic pathways within the muscle sarcomere, making variant interpretation difficult when considering variants in multiple neuromuscular disease--associated genes.

Heterozygous missense mutations of *MYL2* have previously been associated with hypertrophic cardiomyopathy ([@MCS004184MARC25]). More recently, two instances of recessive *MYL2* mutations have been reported to cause a novel autosomal recessive lethal myosinopathy with infantile type I muscle fiber disease and cardiomyopathy ([@MCS004184MARC34]). One of these, a homozygous intronic mutation of *MYL2*, c.403-1G\>C, in a group of related Dutch families resulted in replacement of the last 32 codons with 19 new amino acids. Functional analysis of the resulting protein demonstrated significant conformational alterations and a series of abnormal protein--protein interactions in the cardiac muscle sarcomere, leading to decreased maximal contractile force production and increased calcium sensitivity ([@MCS004184MARC35]), features that likely play a role in the pathogenesis of cardiac failure in our proband. The second instance was found in two Italian siblings with compound heterozygous mutations, c.431delC, p.(Pro144LeufsX2) and c.432delT, p.(Asp145ThrfsX2), in the last exon that both resulted in loss of 20 amino acids at the carboxyl terminus ([@MCS004184MARC34]). Both the Dutch and Italian infants died between the ages of 1 and 6 mo, consistent with the clinical course of our proband. Given the location of our proband\'s truncation in the middle of the protein and presumed consequent complete loss of function, it may be that the carboxy-terminal mutations in the Dutch and Italian infants with similar severity also lead to loss of function, especially because western blot and immunohistochemical staining for MYL2 protein revealed low or undetectable levels of protein in the Dutch patients ([@MCS004184MARC34]).

Careful assessment of molecular consequences, such as predicted effects of the frameshift mutation in the last exon of *NEB* or differential effects on multiple transcripts, as with the *DMD* variant that spared the major full-length muscle isoform, are critical for proper variant interpretation. Careful assessment of the clinical phenotype is equally critical when considering potential relationships between pathogenic variants and a patient\'s medical condition. Although the proband in this study was enrolled on the basis of his hypotonia, weakness, and CFTD in skeletal myofibers, his early-onset fatal cardiomyopathy was a key factor in making a final diagnosis.

In conclusion, this case stresses the importance of multiple methods for variant interpretation and prediction of pathogenicity, including careful phenotyping and correlation with clinical findings, especially when multiple variants are found in genes related to the clinical presentation.

METHODS {#s4}
=======

Next-Generation Panel Testing {#s4a}
-----------------------------

Next-generation sequencing was performed by the Laboratory for Molecular Medicine (LMM) of Partners Healthcare Personalized Medicine using the Agilent SureSelect Design process (<http://personalizedmedicine.partners.org/laboratory-for-molecular-medicine/>). The gene panel utilized an all exon approach for 43 genes of interest for neuromuscular and cardiac conditions ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004184/-/DC1)) by targeting coding exons with bait out to coding sequence (CDS) ±65 bases. The complete coding regions of all genes were sequenced to average depth of 316 reads, with the exception of *CFL2*, *NEB*, *SEPN1*, *TNNT1*, and *TTN*, for which a few exons were excluded because of difficulties in capture. The reportable region of interest was CDS ± 15 bases. For density of probes, a 3× tiling strategy was used. For masking and boosting, a moderately stringent option and maximum performance conditions were used respectively. Specifically, for the DMD gene, in addition to covering all CDS exons ± 65, deletion probes were created every 30 kb within the gene region at a 1× tiling. Next-generation sequencing of paired-end reads was performed on an Illumina HiSeq platform.

In Silico Analysis {#s4b}
------------------

Variant calls were generated using the Burrows--Wheeler Aligner, followed by the Genomic Analysis Tool Kit (GATK). Candidate variants were assessed by reference to the Human Gene Mutation Database (HGMD <http://www.hgmd.cf.ac.uk/ac/index.php>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), and the Genome Aggregation Consortium (gnomAD) database (<http://gnomad.broadinstitute.org>). Candidate variants that were known single-nucleotide polymorphisms (SNPs) were required to have a minor allele frequency of \<0.0001 to be considered for further analysis. SNPs with a minor allele frequency of \>0.0001 were considered to be nonpathogenic. Pathogenicity of variants was predicted by using SIFT (<http://sift.jcvi.org>), PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>), and CADD ([@MCS004184MARC27]), and final determinations of pathogenicity were made following current American College of Medical Genetics guidelines for the interpretation of sequence variants ([@MCS004184MARC28]).

Sanger Sequencing Confirmation {#s4c}
------------------------------

Selected variants were amplified by PCR using standard PCR primers. Amplicons were run in agarose gel electrophoresis and submitted to the Molecular Genetics Core Facility at Boston Children\'s Hospital for sequencing using the ABI Prism BigDye Terminator cycle sequencing protocols (Applied Biosystems, PerkinElmer Corp.). Sequence data were generated in an ABI Prism 3130 or 3730 Genetic Analyzer (Applied Biosystems), formatted by ABI Sequencing Analysis software v.5.2 and KB Basecaller, and analyzed using Sequencher v.5.2.3 or earlier versions (Gene Codes Corporation). Sanger sequencing was performed in affected family members and other family members to confirm pathogenic mutations and track co-segregation patterns.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Variant c.188del p.(Asn63Metfs\*7) in *MYL2* has been submitted to Leiden Open Variation Database (LOVD) with ID number 00367860. Variant c.25435C\>T p.(Gln8479\*) in *NEB* has also been submitted to Leiden Open Variation Database (LOVD) with ID number 00163746. Additional variant calls from analysis of the 43 neuromuscular disease genes in the proband are available from the authors upon reasonable request.
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